RESULTS	Patients in the enzalutamide group had longer median time to HRQoL deterioration than did those in the placebo group ( 90 months , 95 % CI 83-111 , vs 37 months , 95 % CI 30-42 ; HR 045 , 95 % CI 037-055 ; p < 00001 ) in risk of deterioration .\